Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market, 2021-2030.”
The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:
· A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
· Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
· A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
· A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
· A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
· A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
· An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
· A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
· An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
· An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
· A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
· A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
· A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
· A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.
Request for Customization: https://www.rootsanalysis.com/reports/250/request-customization.html
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Commonly Outsourced Business Operations
· Active Pharmaceutical Ingredients (API)
· Finished Dosage Formulations (FDF)
Types of Expression System
· Mammalian
· Microbial
· Others
Company Size
· Small
· Mid-Sized
· Large and Very Large
Scale of Operation
· Preclinical
· Clinical
· Commercial
Key Geographical Region
· North America
· Europe
· Asia-Pacific
· Rest of the World
The report also features detailed transcripts of discussions held with the following experts:
· Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
· Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
· Christian Bailly, Director of CDMO, Pierre Fabre
· Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
· David C Cunningham, Director Corporate Development, Goodwin Biotechnology
· Dietmar Katinger, Chief Executive Officer, Polymun Scientific
· Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
· Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
· Kevin Daley, Director Pharmaceuticals, Novasep
· Mark Wright, Site Head, Grangemouth, Piramal Healthcare
· Nicolas Grandchamp, R&D Leader, GEG Tech
· Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
· Sebastian Schuck, Head of Business Development, Wacker Biotech
· Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
· Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
· Tim Oldham, Chief Executive Officer, Cell Therapies
Key companies covered in the report
· 3P Biopharmaceuticals
· Abzena
· Albany Molecular Research
· BioVectra
· BioXcellence (Boehringer Ingelheim)
· Celonic
· Charles River Laboratories
· ChemPartner
· Cobra Biologics
· CordenPharma
· Cytovance Biologics
· GE Healthcare
· Goodwin Biotechnology
· Grand River Aseptic Manufacturing
· IDT Biologika
· KBI BioPharma
· Kemwell Biopharma
· LFB Biomanufacturing
· Meridian Life Science
· Patheon
· Pfizer CentreOne
· PX’Therapeutics
· Samsung BioLogics
· Sanofi, CEPiA
· Thermo Fisher Scientific
· Vetter Pharma International
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/250/request-sample.html
Also Visit Our Latest Publication:
Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market
Patient Recruitment and Retention Services Market
